RSCM
CERE

Rock Springs Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Rock Springs Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-547,946
Closed -$23.2M – 122
2024
Q1 		$23.2M Sell
547,946
-2,126,299
-80% -$89.3M 0.59% 53
2023
Q4 		$113M Buy
2,674,245
+145,129
+6% +$4.17M 2.79% 9
2023
Q3 		$55.2M Buy
2,529,116
+15,200
+0.6% +$380K 1.48% 23
2023
Q2 		$79.9M Hold
2,513,916
– – 1.9% 15
2023
Q1 		$61.3M Buy
2,513,916
+7,452
+0.3% +$219K 1.46% 23
2022
Q4 		$79.1M Buy
2,506,464
+7,316
+0.3% +$206K 1.9% 18
2022
Q3 		$70.6M Buy
2,499,148
+732,007
+41% +$21.8M 1.82% 15
2022
Q2 		$46.7M Buy
1,767,141
+43,800
+3% +$1.24M 1.36% 26
2022
Q1 		$60.3M Buy
1,723,341
+74,906
+5% +$2.19M 1.52% 22
2021
Q4 		$53.4M Buy
1,648,435
+47,846
+3% +$1.69M 1.23% 29
2021
Q3 		$47.2M Buy
1,600,589
+583,644
+57% +$16.4M 0.99% 34
2021
Q2 		$26.1M Buy
1,016,945
+11,845
+1% +$170K 0.51% 61
2021
Q1 		$13.8M Buy
1,005,100
+6,100
+0.6% +$89.3K 0.3% 92
2020
Q4 		$16.6M Buy
+999,000
New +$13M 0.35% 89

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Rock Springs Capital Management's CERE Position: Q2 2024 in Review

Rock Springs Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 547,946 shares — an estimated $23.2M sold.

Rock Springs Capital Management first reported a position in CERE in Q4 2020 and held it in 14 quarters. The position peaked at $113M in Q4 2023. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • Rock Springs Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Rock Springs Capital Management sold 547,946 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $23.2M.
  • Rock Springs Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Rock Springs Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $113M in Q4 2023.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Rock Springs Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.